Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
*Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials..
*Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials..
*NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and..
*510(k) Submission with FDA Accelerated for Early Second Half of 2024*
*AUSTIN, TX / ACCESSWIRE / May 1, 2024 /..